Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram

Next Previous
Trial Profile

Double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbidopa/oxytriptan (Primary) ; Escitalopram
  • Indications Depressive disorders
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 18 Sep 2023 Status changed from recruiting to completed as per Evecxia Therapeutics media release
  • 25 May 2023 According to an Evecxia Therapeutics media release, trial was conducted at Quotient Sciences Nottingham, UK facility.
  • 25 May 2023 According to an Evecxia Therapeutics media release, data from this trial will be presented at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top